Adherence of patients to the metformin therapy with prolonged action (Glucophage® Long) in real clinical practice in the Russian Federation

• Alexander S. Ametov
• Irina N. Barykina
• Bondar I.A.
• Vaysberg A.R.
• Nelli I. Verbovaya
• Zhukova L.A.
• Zamyatina O.V.
• Kiseleva T.P.
• Tatyana V. Morugova
• Hostalec U.
• Shabalina E.A.

Abstract

Immediate-release metformin (metformin IR) therapy of type 2 diabetes mellitus (DM2) usually prescribed for 2 or 3 times a day. The extended-release formulation (metformin XR) has been developed to allow once-daily dosing which may provide higher compliance and more effective glycemic control. However, these parameters for metformin XR has not been previously evaluated under the Russian Federation in conditions of real clinical practice. The primary objective of the study was to evaluate the Glucophage® Long therapy adherence in daily practice. The secondary objectives included assessing of glycemic control, safety, and tolerability parameters and personal preferences of the patients.

Most patients (n=194, 96.5%) showed a very high (>90%) adherence to the therapy, whereas among the entire cohort the adherence rate was more than 75%. The majority of the patients (n=194, 96.5%) preferred metformin XR to metformin IR. The main reason was the convenience of taking the extended-release formulation (n=178, 88.6%). Higher compliance was accompanied by the improved glycemic control and good tolerability.

These results can be considered as the confirmation of rationality of the choice of Glucophage® Long for the patients with DM2.

Immediate-release metformin (metformin IR) therapy of type 2 diabetes mellitus (DM2) usually prescribed for 2 or 3 times a day. The extended-release formulation (metformin XR) has been developed to allow once-daily dosing which may provide higher compliance and more effective glycemic control. However, these parameters for metformin XR has not been previously evaluated under the Russian Federation in conditions of real clinical practice. The primary objective of the study was to evaluate the Glucophage® Long therapy adherence in daily practice. The secondary objectives included assessing of glycemic control, safety, and tolerability parameters and personal preferences of the patients.

Most patients (n=194, 96.5%) showed a very high (>90%) adherence to the therapy, whereas among the entire cohort the adherence rate was more than 75%. The majority of the patients (n=194, 96.5%) preferred metformin XR to metformin IR. The main reason was the convenience of taking the extended-release formulation (n=178, 88.6%). Higher compliance was accompanied by the improved glycemic control and good tolerability.

These results can be considered as the confirmation of rationality of the choice of Glucophage® Long for the patients with DM2.

Keywords:diabetes, adherence, metformin, Glucophage XR

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)